Abstract：
The primary objective of this study was to assess the diagnostic potential of galectin-3 (Gal-3), fractalkine (FKN), interleukin (IL)-6, microRNA(miR)-21, and cardiac troponin I (cTnI) in patients with ischemic cardiomyopathy (ICM).
A total of 78 ICM patients (Case group) and 80 healthy volunteers (Control group) admitted to our hospital for treatment or physical examination from Aug. 2018 to Feb. 2020 were included in the current study. The serum concentration of Gal-3, FKN, IL-6, miR-21, and plasma expression of cTnI of both groups were determined. The severity of ICM was classified using New York Heart Association (NYHA) scale.
When compared with the control group, the case group had a significantly high blood concentration of Gal-3, FKN, IL-6, miR-21, and cTnI (P < 0.001). NYHA class II patients had lower blood levels of Gal-3, FKN, IL-6, miR-21, and cTnI than that in patients of NYHA class III and IV without statistical significance (P > 0.05). However, statistical significance could be achieved when comparing the above-analyzed markers in patients classified between class III and IV. Correlation analysis also revealed that serum levels of Gal-3, FKN, IL-6, miR-21, and cTnI were positively correlated with NYHA classification (R = 0.564, 0.621, 0.792, 0.981, P < 0.05).
Our study revealed that up-regulated serum Gal-3, FKN, IL-6, miR-21, and cTnI levels were closely related to the progression of ICM. This association implies that these biomarkers have diagnostic potential, offering a promising avenue for early detection and monitoring of ICM progression.
A total of 78 ICM patients (Case group) and 80 healthy volunteers (Control group) admitted to our hospital for treatment or physical examination from Aug. 2018 to Feb. 2020 were included in the current study. The serum concentration of Gal-3, FKN, IL-6, miR-21, and plasma expression of cTnI of both groups were determined. The severity of ICM was classified using New York Heart Association (NYHA) scale.
When compared with the control group, the case group had a significantly high blood concentration of Gal-3, FKN, IL-6, miR-21, and cTnI (P < 0.001). NYHA class II patients had lower blood levels of Gal-3, FKN, IL-6, miR-21, and cTnI than that in patients of NYHA class III and IV without statistical significance (P > 0.05). However, statistical significance could be achieved when comparing the above-analyzed markers in patients classified between class III and IV. Correlation analysis also revealed that serum levels of Gal-3, FKN, IL-6, miR-21, and cTnI were positively correlated with NYHA classification (R = 0.564, 0.621, 0.792, 0.981, P < 0.05).
Our study revealed that up-regulated serum Gal-3, FKN, IL-6, miR-21, and cTnI levels were closely related to the progression of ICM. This association implies that these biomarkers have diagnostic potential, offering a promising avenue for early detection and monitoring of ICM progression.
摘要：
目的：本研究的主要目的是评估半乳糖凝集素-3（Gal-3）的诊断潜力，Fractalkine(FKN),缺血性心肌病（ICM）患者的白细胞介素（IL）-6，微小RNA（miR）-21和心肌肌钙蛋白I（cTnI）。
方法：共78例ICM患者（病例组）和80例健康志愿者（对照组）从8月开始入院治疗或体检2018年2月2020年被纳入本研究。血清中Gal-3、FKN、测定两组的IL-6、miR-21和cTnI的血浆表达。使用纽约心脏协会（NYHA）量表对ICM的严重程度进行分类。
结果：与对照组相比，病例组Gal-3、FKN、IL-6、miR-21和cTnI(P<0.001)。NYHAII级患者的Gal-3，FKN，IL-6、miR-21和cTnI比NYHAⅢ级和Ⅳ级患者无统计学意义(P>0.05)。然而,在分类为III类和IV类的患者中比较上述分析的标志物时,可以获得统计学显著性.相关分析还显示，血清Gal-3、FKN、IL-6、miR-21和cTnI与NYHA分级呈正相关(R=0.564、0.621、0.792、0.981,P<0.05)。
结论：我们的研究表明，血清Gal-3，FKN，IL-6、miR-21和cTnI水平与ICM进展密切相关。这种关联意味着这些生物标志物具有诊断潜力，为早期发现和监测ICM进展提供了一个有希望的途径。
方法：共78例ICM患者（病例组）和80例健康志愿者（对照组）从8月开始入院治疗或体检2018年2月2020年被纳入本研究。血清中Gal-3、FKN、测定两组的IL-6、miR-21和cTnI的血浆表达。使用纽约心脏协会（NYHA）量表对ICM的严重程度进行分类。
结果：与对照组相比，病例组Gal-3、FKN、IL-6、miR-21和cTnI(P<0.001)。NYHAII级患者的Gal-3，FKN，IL-6、miR-21和cTnI比NYHAⅢ级和Ⅳ级患者无统计学意义(P>0.05)。然而,在分类为III类和IV类的患者中比较上述分析的标志物时,可以获得统计学显著性.相关分析还显示，血清Gal-3、FKN、IL-6、miR-21和cTnI与NYHA分级呈正相关(R=0.564、0.621、0.792、0.981,P<0.05)。
结论：我们的研究表明，血清Gal-3，FKN，IL-6、miR-21和cTnI水平与ICM进展密切相关。这种关联意味着这些生物标志物具有诊断潜力，为早期发现和监测ICM进展提供了一个有希望的途径。
